Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives

BACKGROUND: Bevacizumab remains the most widely used and most thoroughly characterized angiogenesis inhibitor for a range of advanced cancers. Bevacizumab-bvzr (Zirabev(®)), a biosimilar of bevacizumab, was recently approved by the US Food and Drug Administration (FDA), which provides a less costly...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jingyan, Liu, Rongzhe, Ektare, Varun, Stephens, Jennifer, Shelbaya, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270829/
https://www.ncbi.nlm.nih.gov/pubmed/33506318
http://dx.doi.org/10.1007/s40258-021-00637-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270829/
https://www.ncbi.nlm.nih.gov/pubmed/33506318
http://dx.doi.org/10.1007/s40258-021-00637-5

Ejemplares similares